Melanoma Research Institute of Excellence
Contact
Position:
Program Manager
Organization:
Melanoma Research Institute of Excellence
Contact Number(s):
Contact
Positions:
- Assistant Program Manager
- Director of Database Design and Utilization
Organization:
Melanoma Research Institute of Excellence
Email:
Shingo.Sato@jefferson.edu
Contact Number(s):
Clinical Trials
Marlana Orloff, MD
Principal Investigator
| A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer |
| APG-115-US-002: A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors |
| A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions |
| A Phase I/Ib, Open-Label Study of the Pressure-Enabled hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Metastatic Uveal Melanoma |
| IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-Line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma |
Takami Sato, MD, PhD
Principal Investigator
| A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers |
| A Study for the In Vitro Detection and Analysis of Circulating Biomarkers in Melanoma Patients from a Blood Draw |
Carin Gonsalves, MD
Principal Investigator
Rino Seedor, MD
Principal Investigator
| A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors |
| A Phase II Trial of Defactinib (VS-6063) Combined with VS-6766 (CH5126766) in Patients with Metastatic Uveal Melanoma |
| A Phase II Study of Concurrent Stereotactic Body Radiotherapy with Relatlimab and Nivolumab in Patients with Metastatic Uveal Melanoma |
| A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma |
| Geospatial Distribution of Uveal Melanoma |
| Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma |
Clinical Research Staff